#PhaseV
PhaseV Unveils BonV: A Revolutionary AI Orchestrator for Clinical Decision-Making#USA#Cambridge#PhaseV#AI_Orchestrator#BonV
PhaseV Unveils BonV: A Revolutionary AI Orchestrator for Clinical Decision-Making
PhaseV's new AI orchestrator, BonV, revolutionizes clinical decision-making by turning complex questions into actionable, evidence-based outcomes for biopharma teams.
third-news.com
November 3, 2026 at 1:43 PM
PhaseV's New Model Provides Insights into GLP-1 Treatment Outcomes Based on Real-World Data#USA#Boston#PhaseV#Veradigm#GLP-1
PhaseV's New Model Provides Insights into GLP-1 Treatment Outcomes Based on Real-World Data
PhaseV has unveiled a predictive model that uses real-world data to assess GLP-1 treatment side effects and patient dropout risks, enhancing clinical trial strategies.
third-news.com
October 14, 2026 at 12:49 PM
PhaseV Strengthens Leadership with Biopharma Experts Klaus Beck and Avi Kulkarni for AI Development#United_States#Boston#PhaseV#Avi_Kulkarni#Klaus_Beck
PhaseV Strengthens Leadership with Biopharma Experts Klaus Beck and Avi Kulkarni for AI Development
PhaseV has appointed Klaus Beck and Avi Kulkarni to its Scientific Advisory Board, aiming to enhance the AI Conductor platform for clinical development.
third-news.com
September 16, 2026 at 12:35 PM
PhaseV Lands $50M Series A to Supercharge AI for Clinical Development, Backed by Top VCs and Trusted by Leading Pharma Clients #healthIT #PhaseV
www.healthcareittoday.com/?p=2523772
June 6, 2025 at 6:00 PM
PhaseV unveiled Enrollment Lab, adding AI-powered enrollment modeling to its ClinOps platform to quantify real-world patient access. #DataScience #AI #ArtificialIntelliigence opendatascience.com/phasev-launc...
PhaseV Launches Enrollment Lab to Model Trial Enrollment Before Protocol Lock
PhaseV has launched Enrollment Lab, a new AI-powered solution designed to quantify a clinical study’s enrollment potential and model protocol trade-offs earlier in planning—before protocol lock and pr...
opendatascience.com
February 19, 2026 at 12:15 PM
PhaseV unveiled Enrollment Lab, adding AI-powered enrollment modeling to its ClinOps platform to quantify real-world patient access. #DataScience #AI #ArtificialIntelliigence opendatascience.com/phasev-launc...
PhaseV Launches Enrollment Lab to Model Trial Enrollment Before Protocol Lock
PhaseV has launched Enrollment Lab, a new AI-powered solution designed to quantify a clinical study’s enrollment potential and model protocol trade-offs earlier in planning—before protocol lock and pr...
opendatascience.com
February 10, 2026 at 10:19 AM
At the 17th Annual SCOPE Summit, PhaseV officially launched its AI-powered Enrollment Lab, a system that replaces theoretical study planning with evidence-based certainty by leveraging real-world Electronic Health Record (EHR) data.

#AI #PhaseV #ClinicalTrials #MedTech
February 3, 2026 at 3:19 AM
Boston-based PhaseV, which is developing AI software to accelerate clinical trials and drug development, raised a $50M Series A co-led by Accel and Insight (Aaron Weitzman/Axios)

Main Link | Techmeme Permalink
May 17, 2025 at 5:31 AM
New partnership between PhaseV and Crohn’s & Colitis Foundation leverages #AI and #RWD to transform #IBD trials | Becaris Publishing becarispublishing.com/digital-cont...
New partnership between PhaseV and Crohn’s & Colitis Foundation leverages AI and RWD to transform IBD trials | Becaris Publishing
becarispublishing.com
June 2, 2025 at 10:27 AM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, March 18, 2026
PhaseV unveils centralised platform to automate clinical trials
PhaseV has launched the AI Conductor centralised platform designed to automate every stage in clinical trial process from drafting protocols to submitting final reports.
www.clinicaltrialsarena.com
March 18, 2026 at 5:57 PM
Feed: "Techmeme"
Published on Saturday, May 17, 2025
Boston-based PhaseV, which is developing AI software to accelerate clinical trials and drug development, raised a $50M Series A co-led by Accel and Insight (Aaron Weitzman/Axios)
By Aaron Weitzman / Axios. View the full context on Techmeme.
www.techmeme.com
May 17, 2025 at 10:36 AM
動画投稿しましたー
総力戦PHASEⅤに挑戦!3戦分の編成を用意しました!【ティンクルスターナイツ】
youtu.be/TRbWVWJE2q4
総力戦PHASEⅤに挑戦!3戦分の編成を用意しました!【ティンクルスターナイツ】
YouTube video by ぬぅちゃんねる
youtu.be
October 12, 2024 at 1:06 PM
Head to the EXPO for JSM Spotlight treats & activities: Coffee House at 10 a.m.; Photo Booth, sponsored by SAS, from 11 a.m. to 2 p.m.; New England Cheese at 1 p.m.; and Microbrew Tasting, sponsored by PhaseV Trials, at 3:30 p.m. (while supplies last). tinyurl.com/r3x7pyry #JSM2026 #STATSSKY
August 3, 2026 at 1:24 PM
The #JSM2025 Spotlight in the EXPO is hopping today. The Coffee House opens at 10:00 a.m. for both coffee and tea. At 1:30 p.m., pick up a tasty bag of popcorn, then head back over at 3:30 p.m. for a microbrew (while supplies last). Cheers to PhaseV Trials for their sponsorship. #statssky
August 4, 2025 at 2:35 PM
AI is reshaping drug discovery and clinical trials, prompting the FDA to weigh new patient safety rules. Firms like PhaseV and BioPhy use AI for precise patient matching and trial diversity, enhancing efficiency but narrowing commercial reach. 🩺🖥️ #MLSky 💊
How A.I. Is Disrupting Pharma: The High-Stakes Race to Revolutionize Drug Discovery
While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.
observer.com
November 14, 2024 at 4:18 PM
🔬 This week in biotech VC: AI & precision immunotherapies lead. Somite $47 M, PhaseV $50 M, TILT Biotherapeutics $25.6 M, Avammune $12 M & HAYA $65 M drive next-gen therapies. We round up the investments you should know about → www.ventureradar.com/articles/May...

HASHTAGS
#Biotech #VC #Investing
May 14th – State of Biotech VC: Key Investment Trends from the Past Week | VentureRadar
May 14th – State of Biotech VC: Key Investment Trends from the Past Week
www.ventureradar.com
May 15, 2025 at 1:35 PM
New PhaseV Survey Highlights Operational Delays in Clinical Trials Impacting Pharmaceutical Development#USA#Boston#Clinical_Trials#PhaseV#AI_Conductor
New PhaseV Survey Highlights Operational Delays in Clinical Trials Impacting Pharmaceutical Development
A recent PhaseV survey reveals alarming delays in clinical trial processes, with 88% of sponsors facing five or more weeks due to vendor fragmentation. This highlights a crucial need for automation.
third-news.com
August 17, 2026 at 12:45 PM
PhaseV Introduces Integrated AI Solutions to Revolutionize Clinical Trials in 2026#United_States#Boston#Clinical_Trials#PhaseV#AI/ML
PhaseV Introduces Integrated AI Solutions to Revolutionize Clinical Trials in 2026
PhaseV is set to showcase its innovative AI/ML solutions at key conferences in 2026, aiming to enhance clinical trial efficiency and patient outcomes.
third-news.com
March 26, 2026 at 12:57 PM
Revolutionizing Clinical Trials: PhaseV's AI Conductor Streamlines Submission Workflows#USA#Boston#Clinical_Trials#PhaseV#AI_Conductor
Revolutionizing Clinical Trials: PhaseV's AI Conductor Streamlines Submission Workflows
PhaseV has unveiled its AI Conductor platform, which automates every aspect of clinical trial workflows, from protocol drafting to FDA submission readiness.
third-news.com
March 17, 2026 at 1:15 PM
PhaseV Achieves Record Growth as Biopharma Shifts Towards AI Execution for Clinical Trials#None#Boston#PhaseV#Biopharma#AI/ML
PhaseV Achieves Record Growth as Biopharma Shifts Towards AI Execution for Clinical Trials
PhaseV has experienced significant growth in 2025, transitioning from AI pilots to full-scale clinical execution, supported by major funding and industry partnerships.
third-news.com
December 16, 2025 at 1:57 PM